Docket Number:12A-1030317
Inventor:Te-Chang Lee, Tsann-Long Su
IP Status:US Provisional
Abstract:
We have recently designed and synthesized a series of indolizino[6,7-b]indole derivatives, which were designed as hybrid molecules of -carboline (topoisomerase I and II inhibitory moiety) and bis(hydroxymethyl)pyrrole (DNA cross-linking moiety). We demonstrated that these hybrid molecules exhibited potent antitumor activity both in vitro and in tumor xenograft models. Interestingly, we found that these derivatives possess multi-mode of action; inhibition of topo I and topo II and induction of DNA cross-linking. More recently, of these derivatives we found that compounds BO-1098 and BO-1922 exhibited significant cytotoxicity against cell growth of various human non-small cell lung cancer cell lines (NSCLC) in vitro and potent therapeutic efficacy in tumor xenograft or orthotopic models. Remarkably, it revealed that the combination of BO-1978 with Gefitinib (or Iressa), which is an inhibitor of epidermal growth factor receptor (EGFR) and was used as a targeted therapeutic agent for treating non-small cell lung cancer (NSCLC) in clinics, showed significantly synergistic efficacy against EGFR-mutated NSCLC (PC9 cells and its Gefitinib-resistant subline PC9/gef B4) in vitro and in vivo. The therapeutic efficacy of the combination (BO-1978 + Gefitinib) in PC9/gef B4 bearing mice is greater than that when tumor bearing mice (xenograft and orthotopic models) were treated with Gefinitib, Cisplatin, or BO compounds alone. In addition, the early preclinical studies showed that BO-1922 and BO-1978 did not cause obviously acute toxicity in the drug-treated mice based on pathology of various organs and blood biochemistry examination. We conclude that indolizino[6,7-b]indole derivatives have high potential for cancer combination therapy.
Fields of Application:
Treatment of non-small cell lung cancers, especially for EGFR mutated non-small cell lung cancers which are resistant to EGFR inhibitor (such as Gefitinib).
Advantages when compared to the existing technologies:
The therapeutic efficacy of BO-1978 + Gefitinib is superior to that of EGFR inhibitor (such as Gefitinib), cisplatin or BO compound alone in xenograft or orthotopic models. BO-1978 exhibits multi-mode of mechanism actions, low toxicity with high bioavailability in animals. All these together, it indicates that there is high potential to develop BO-1978 as a clinical use drug for the treatment of NSCLC or EGFR mutated NSCLC.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
